<DOC>
	<DOC>NCT01698697</DOC>
	<brief_summary>This trial is conducted in Africa. The aim of this trial is to determine if a new formulation (U200) of insulin aspart containing 200 U/mL is bioequivalent to that of a marketed insulin aspart formulation (U100).</brief_summary>
	<brief_title>Comparison of Two Insulin Aspart Formulations in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Normal findings in medical history and physical examination unless the investigator considers any abnormality to be clinically irrelevant Normal laboratory values, electrocardiogram (ECG), and vital signs unless the investigator considers any abnormality to be clinically irrelevant Body mass index (BMI) 1826 kg/m^2 (both inclusive) Weight 6090 kg Nonsmoker Any condition requiring the regular use of any medication Known or suspected allergy to the trial product or related products Family history of type 1 diabetes mellitus</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>